3903 related articles for article (PubMed ID: 7059953)
21. Local and systemic toxicity in 'borderline true' hyperthermic isolated perfusion for lower limb melanoma.
Pace M; Galli A; Bellacci A
Melanoma Res; 1995 Oct; 5(5):371-6. PubMed ID: 8541729
[TBL] [Abstract][Full Text] [Related]
22. Proliferation, phenotype, and cytotoxicity of human lymphocytes isolated from lymph nodes invaded by melanoma cells.
Nakashima M; Janiszewska M; Steplewski Z; Watanabe T; Schuchter L; Koprowski H
Hybridoma; 1994 Jun; 13(3):241-6. PubMed ID: 7927369
[TBL] [Abstract][Full Text] [Related]
23. Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapy.
Clementi E; Bucci E; Citterio G; Landonio G; Consogno G; Fortis C
Cancer Immunol Immunother; 1994 Sep; 39(3):167-71. PubMed ID: 7923246
[TBL] [Abstract][Full Text] [Related]
24. Plasmodium falciparum: CD36 dependent cytoadherence or rosetting of infected erythrocytes is modulated by knobs.
Crandall I; Guthrie N; Demers D; Sherman IW
Cell Adhes Commun; 1994 Dec; 2(6):503-10. PubMed ID: 7538019
[TBL] [Abstract][Full Text] [Related]
25. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo.
Barnhill RL; Xiao M; Graves D; Antoniades HN
Br J Dermatol; 1996 Dec; 135(6):898-904. PubMed ID: 8977709
[TBL] [Abstract][Full Text] [Related]
26. Initial in vivo experience with EIT as a thermal estimator during hyperthermia.
Paulsen KD; Moskowitz MJ; Ryan TP; Mitchell SE; Hoopes PJ
Int J Hyperthermia; 1996; 12(5):573-91; discussion 593-4. PubMed ID: 8886886
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of autocrine-motility-factor-like activity in oral squamous-cell-carcinoma cells.
Ishisaki A; Oida S; Momose F; Amagasa T; Rikimaru K; Ichijo H; Sasaki S
Int J Cancer; 1994 Dec; 59(6):783-8. PubMed ID: 7989119
[TBL] [Abstract][Full Text] [Related]
28. Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines.
Berger W; Elbling L; Minai-Pour M; Vetterlein M; Pirker R; Kokoschka EM; Micksche M
Int J Cancer; 1994 Dec; 59(5):717-23. PubMed ID: 7960246
[TBL] [Abstract][Full Text] [Related]
29. Skin cancer. Recognition and treatment.
Marks R; Motley RJ
Drugs; 1995 Jul; 50(1):48-61. PubMed ID: 7588089
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant interferon treatment for melanoma.
Agarwala SS; Kirkwood JM
Hematol Oncol Clin North Am; 1998 Aug; 12(4):823-33. PubMed ID: 9759581
[TBL] [Abstract][Full Text] [Related]
31. Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A.
Martinetti A; Seregni E; Belli F; Mazzocchi A; Agresti R; Cascinelli N; Greco M; Bombardieri E
Anticancer Res; 1998; 18(3B):2027-30. PubMed ID: 9677461
[TBL] [Abstract][Full Text] [Related]
32. The management of squamous cell vulval cancer: a population based retrospective study of 411 cases.
Rhodes CA; Cummins C; Shafi MI
Br J Obstet Gynaecol; 1998 Feb; 105(2):200-5. PubMed ID: 9501787
[TBL] [Abstract][Full Text] [Related]
33. Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine.
van Elsas A; Aarnoudse C; van der Minne CE; van der Spek CW; Brouwenstijn N; Osanto S; Schrier PI
J Immunother; 1997 Sep; 20(5):343-53. PubMed ID: 9336741
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral heterogeneity for and epigenetic modulation of mdr-1 expression in murine melanoma.
Yoon SS; Fidler IJ; Beltran PJ; Bucana CD; Wang YF; Fan D
Melanoma Res; 1997 Aug; 7(4):275-87. PubMed ID: 9293477
[TBL] [Abstract][Full Text] [Related]
35. Second primary tumors in patients with retinoblastoma. A review of the literature.
Moll AC; Imhof SM; Bouter LM; Tan KE
Ophthalmic Genet; 1997 Mar; 18(1):27-34. PubMed ID: 9134547
[TBL] [Abstract][Full Text] [Related]
36. Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer cells.
Paus E; Myklebust AT
Tumour Biol; 1996; 17(5):271-80. PubMed ID: 8792853
[TBL] [Abstract][Full Text] [Related]
37. Small-diameter invasive melanomas: clinical and pathologic characteristics.
Gonzalez A; West AJ; Pitha JV; Taira JW
J Cutan Pathol; 1996 Apr; 23(2):126-32. PubMed ID: 8721446
[TBL] [Abstract][Full Text] [Related]
38. Long-term complications of reconstruction of the heel using a digitorum brevis muscle flap.
Furukawa M; Nakagawa K; Hamada T
Ann Plast Surg; 1993 Apr; 30(4):354-8. PubMed ID: 8512293
[TBL] [Abstract][Full Text] [Related]
39. Exploitation of pigment biosynthesis pathway as a selective chemotherapeutic approach for malignant melanoma.
Jimbow K; Iwashina T; Alena F; Yamada K; Pankovich J; Umemura T
J Invest Dermatol; 1993 Feb; 100(2 Suppl):231S-238S. PubMed ID: 8433013
[TBL] [Abstract][Full Text] [Related]
40. The National Cancer Data Base. A mechanism for assessment of patient care.
Steele GD; Winchester DP; Menck HR
Cancer; 1994 Jan; 73(2):499-504. PubMed ID: 8293419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
